队列简介：PharmAccess非洲（PASER-M）和亚太地区治疗（TASER-M）监测研究，以评估撒哈拉以南非洲和亚太地区的耐药性——艾滋病毒耐药性。 - Suppr

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

作者信息

Hamers Raph L, Oyomopito Rebecca, Kityo Cissy, Phanuphak Praphan, Siwale Margaret, Sungkanuparph Somnuek, Conradie Francesca, Kumarasamy Nagalingeswaran, Botes Mariette E, Sirisanthana Thira, Abdallah Saade, Li Patrick C K, Ngorima Nicoletta, Kantipong Pacharee, Osibogun Akin, Lee Christopher K C, Stevens Wendy S, Kamarulzaman Adeeba, Derdelinckx Inge, Chen Yi-Ming Arthur, Schuurman Rob, van Vugt Michèle, Rinke de Wit Tobias F

机构信息

PharmAccess Foundation, Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.

DOI:10.1093/ije/dyq192

PMID:21071386

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3304520/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e8/3304520/1b3a3c497d54/dyq192f1.jpg

相似文献

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.队列简介：PharmAccess非洲（PASER-M）和亚太地区治疗（TASER-M）监测研究，以评估撒哈拉以南非洲和亚太地区的耐药性——艾滋病毒耐药性。

Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.撒哈拉以南非洲地区一线抗反转录病毒治疗中预处理 HIV-1 耐药性对免疫、病毒学和耐药性结局的影响：一项多中心队列研究。

Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27.

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.治疗前的 HIV 耐药性会增加撒哈拉以南非洲地区的治疗方案转换。

Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.

Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America.在撒哈拉以南非洲、亚太地区以及中南美洲国家，开始联合抗逆转录病毒治疗后，艾滋病毒感染者贫血的短期风险。

J Int AIDS Soc. 2012 Jan 30;15(1):5. doi: 10.1186/1758-2652-15-5.

[AIDS treatment in Africa: the risk of antiretroviral resistance].非洲的艾滋病治疗：抗逆转录病毒耐药性风险

Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2666-71.

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.艾滋病毒耐药性对撒哈拉以南非洲地区与艾滋病毒/艾滋病相关的死亡率、新感染率及抗逆转录病毒治疗项目成本的影响

J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089.

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.撒哈拉以南非洲地区成人和儿童一线抗逆转录病毒治疗持续病毒学失败后HIV-1耐药性的累积

J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.

Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network.建立艾滋病病毒耐药性评估能力：PharmAccess 非洲耐药评估研究网络的经验。

Clin Infect Dis. 2012 May;54 Suppl 4:S261-5. doi: 10.1093/cid/cir995.

Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries.基于人群的 6 个非洲国家 HIV 耐药性监测的早期预警指标。

Clin Infect Dis. 2012 May;54 Suppl 4:S294-9. doi: 10.1093/cid/cir1015.

The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.评估撒哈拉以南非洲地区艾滋病毒耐药性检测的REVAMP试验：资源有限环境下临床试验设计的案例研究，以优化有效性和成本效益估计。

HIV Clin Trials. 2017 Jul;18(4):149-155. doi: 10.1080/15284336.2017.1349028. Epub 2017 Jul 18.

引用本文的文献

The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation.拉各斯大学教学医院中 HIV-1 亚型对病毒学和免疫学治疗结果的影响：一项纵向评估。

PLoS One. 2020 Aug 25;15(8):e0238027. doi: 10.1371/journal.pone.0238027. eCollection 2020.

Access to HIV Viral Load Testing and Antiretroviral Therapy Switch Practices: A Multicountry Prospective Cohort Study in Sub-Saharan Africa.在撒哈拉以南非洲进行的一项多国前瞻性队列研究：艾滋病毒病毒载量检测和抗逆转录病毒治疗转换实践的可及性。

AIDS Res Hum Retroviruses. 2020 Nov;36(11):918-926. doi: 10.1089/AID.2020.0049. Epub 2020 Aug 27.

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.比较在乌干达接受基于替诺福韦和齐多夫定的一线方案治疗的患者中，HIV-1 亚型 A 和 D 之间的 HIV 耐药性特征。

AIDS Res Ther. 2020 Jan 31;17(1):2. doi: 10.1186/s12981-020-0258-7.

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.简化撒哈拉以南非洲的二线抗逆转录病毒治疗转换：使用单一病毒载量定义依非韦伦为基础的一线治疗失败的预测效果。

AIDS. 2019 Aug 1;33(10):1635-1644. doi: 10.1097/QAD.0000000000002234.

Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.撒哈拉以南非洲和亚洲地区艾滋病毒抗逆转录病毒治疗的依从性：两个区域队列的比较分析。

J Int AIDS Soc. 2017 Mar 3;20(1):21218. doi: 10.7448/IAS.20.1.21218.

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How.艾滋病病毒预防的暴露前预防：为何、是什么、何人适用及如何实施。

Infect Dis Ther. 2016 Dec;5(4):407-416. doi: 10.1007/s40121-016-0128-8. Epub 2016 Sep 27.

Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort.亚洲地区HIV阳性队列中的吸烟情况及预测的心血管疾病风险

HIV Med. 2016 Aug;17(7):542-9. doi: 10.1111/hiv.12358.

Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda.在乌干达使用干血斑对一种经济实惠的HIV定性病毒学失败检测方法进行临床评估

PLoS One. 2016 Jan 29;11(1):e0145110. doi: 10.1371/journal.pone.0145110. eCollection 2016.

Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo.多哥半农村地区艾滋病诊所中接受一线抗逆转录病毒治疗的HIV-1感染患者的病毒学转归

AIDS Res Ther. 2015 Nov 27;12:38. doi: 10.1186/s12981-015-0082-7. eCollection 2015.

Risk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B.感染人类免疫缺陷病毒1型（HIV-1）流行重组型（CRF）01_AE和B亚型的东南亚患者的风险组特征及病毒传播簇

Kaohsiung J Med Sci. 2015 Sep;31(9):445-53. doi: 10.1016/j.kjms.2015.07.002. Epub 2015 Aug 21.

本文引用的文献

HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia.在赞比亚卢萨卡，开始接受抗逆转录病毒治疗的患者中有 6%存在 HIV-1 耐药突变。

J Acquir Immune Defic Syndr. 2010 Sep;55(1):95-101. doi: 10.1097/QAI.0b013e3181e544e0.

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.根据世界卫生组织指南接受治疗的成人HIV-1感染者的病毒学监测及对一线高效抗逆转录病毒治疗的耐药性：一项系统评价和荟萃分析

Lancet Infect Dis. 2009 Jul;9(7):409-17. doi: 10.1016/S1473-3099(09)70136-7.

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.亚太地区治疗质量评估方案（TAQAS），旨在规范一组亚洲实验室中HIV基因耐药性检测的结果。

J Virol Methods. 2009 Aug;159(2):185-93. doi: 10.1016/j.jviromet.2009.03.016. Epub 2009 Mar 26.

Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.在北美和西欧两项临床试验筛查中，初治抗逆转录病毒治疗受试者中传播的HIV-1耐药性的地理和时间趋势。

HIV Clin Trials. 2009 Mar-Apr;10(2):94-103. doi: 10.1310/hct1002-94.

Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.HIV-1非B亚型之间的基因多样性在耐药性中的作用：病毒学和生化证据的系统评价

AIDS Rev. 2008 Oct-Dec;10(4):212-23.

The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.撒哈拉以南非洲地区人类免疫缺陷病毒1型对抗逆转录病毒药物的耐药状况。

Antivir Ther. 2008;13(5):625-39.

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.抗逆转录病毒疗法的公共卫生与个体方法：南非乡镇与瑞士的比较

PLoS Med. 2008 Jul 8;5(7):e148. doi: 10.1371/journal.pmed.0050148.

The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.世界卫生组织预防和评估艾滋病毒耐药性的全球战略。

Antivir Ther. 2008;13 Suppl 2:1-13.

World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.世界卫生组织/艾滋病耐药性网络耐药性实验室战略

Antivir Ther. 2008;13 Suppl 2:49-57.

World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.世界卫生组织开展调查，以监测哨点抗逆转录病毒治疗点的艾滋病毒耐药性预防情况及相关因素。

Antivir Ther. 2008;13 Suppl 2:15-23.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献